What benefit and harms were identified in the review of the risks tools?
The review of the risks tools identified a trade-off between clinical benefits and harms. The estimated AUC for the SHFM tool ranged from 0.66 to 0.76 across the 10 cohort datasets. At the clinically relevant thresholds, the sensitivity of the SHFM tool was very low, estimated at 0.5% for a threshold of 50% predicted mortality, and 20.7% at 20% predicted mortality. However, the specificity of the tool was high, 99.9% at the 50% predicted mortality threshold and 93.1% at the 20% predicted morality threshold. 